Over the past several years, genetic counselling and screening of BRCA1 founder mutations have covered more than 50% of all breast and ovarian cancer cases registered in Latvia each year, thus providing information about the prevalence of hereditary cancer syndromes and BRCA1 founder mutations in unselected groups of breast and ovarian cancer patients. Here, BRCA1 is linked to ovarian carcinoma.